三棱丸对肠纤维化大鼠血管生成的影响
|
摘要
目的探讨三棱丸对肠纤维化大鼠VEGF的影响。方法将40只SD大鼠随机分成三棱丸低、中、高剂量组,空白对照组,模型组,每组8只。空白对照组无任何干预措施,其它4组以5%的2,4,5-三硝基苯磺酸(TNBS)灌肠造模,诱导形成大鼠的肠纤维化模型;治疗组以高、中、低不同浓度(10.0,5.0,2.5 g/kg)的三棱丸水煎剂灌胃,每日1次;模型组、空白对照组以等体积生理盐水灌胃,所有大鼠在给药35 d后处死,作病理学分析,并采用Western blot和qPCR法检测结肠组织中钙粘附蛋白E(E-cadherin)、α平滑肌肌动蛋白(α-SMA)、Ⅰ型胶原(colllagenⅠ)、血管内皮生长因子(VEGF)的转录和表达。结果三棱丸高、中剂量均能抑制大鼠肠纤维化程度,下调colllagenⅠ、VEGF的转录和表达水平(P<0.05),三棱丸高剂量作用更显著。结论三棱丸可以通过下调VEGF表达水平,发挥抗肠纤维化的作用。
OBJECTIVE To investigate the effect of Sparganii pill on the expression of VEGF of intestinal fibrosis model rats. METHODS 40 SD rats were randomly divided into SparganiI pill low, middle and high dose treatment groups, control group and model group. 5% TNBS was used to establish an intestinal fibrosis model. Starting from modeling, rats were given SparganiI pill decoction with different concentrations(10.0, 5.0, 2.5 g/kg) orally once a day; 0.8 mL saline were given in the model and control groups. 35 d later, the colon specimens were collected to make pathology evaluation and the levels of E-cadherin, α-SMA, collagen Ⅰ and VEGF were detected by Western blot and qPCR assay. RESULTS Compared with the model group, Sparganii pill in high and middle dose groups inhibited the degree of intestinal fibrosis and reduced the levels of expression of collagen Ⅰ and VEGF. The effect of the high dose group of Sparganii pill was more significant. CONCLUSION Sparganii pill decoction shows an effect of anti-intestinal fibrosis by down-regulating the expression level of VEGF.
OBJECTIVE To investigate the effect of Sparganii pill on the expression of VEGF of intestinal fibrosis model rats. METHODS 40 SD rats were randomly divided into SparganiI pill low, middle and high dose treatment groups, control group and model group. 5% TNBS was used to establish an intestinal fibrosis model. Starting from modeling, rats were given SparganiI pill decoction with different concentrations(10.0, 5.0, 2.5 g/kg) orally once a day; 0.8 mL saline were given in the model and control groups. 35 d later, the colon specimens were collected to make pathology evaluation and the levels of E-cadherin, α-SMA, collagen Ⅰ and VEGF were detected by Western blot and qPCR assay. RESULTS Compared with the model group, Sparganii pill in high and middle dose groups inhibited the degree of intestinal fibrosis and reduced the levels of expression of collagen Ⅰ and VEGF. The effect of the high dose group of Sparganii pill was more significant. CONCLUSION Sparganii pill decoction shows an effect of anti-intestinal fibrosis by down-regulating the expression level of VEGF.
引文
[1] BURKE JP,MULSOW JJ,O'KEANE C,et al.Fibrogenesis in Crohn's disease[J].Am J Gastroenterol,2007,102(2):439-448.
[2] 徐速,陈浩,曾莉.三棱丸方加减治疗克罗恩病肠道纤维化36例疗效观察[J].结直肠肛门外科杂志,2014,20(6):433-434.
[3] 徐速,曾莉.三棱丸方对克罗恩病肠纤维化中血小板活化治疗作用的研究[J].陕西中医,2017,38(2):144-146.
[4] 徐速,曾莉.三棱丸方对肠上皮细胞上皮间质转化TGFβ1/Smads信号通路的影响[J].辽宁中医杂志,2017,44(1):125-127.
[5] 徐速,曾莉.三棱丸方干预克罗恩病大鼠肠壁纤维化的作用研究[J].辽宁中医杂志,2016,43(10):2188-2191.
[6] VIDELA S,VILASECA J,MEDINA C,et al.Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis[J].J Pharmacol Exp Ther,2006,316(2):940-945.
[7] 吕永慧.克罗恩病的中医诊治思路[J].现代消化及介入诊疗,2010,15(4):244-247.
[8] 姚俊.经验良方全集[M].北京:中国中医药出版社,1995:135-137.
[9] 沈丕安.以活血化瘀为主治疗腹腔内炎性肿块2例[J].上海中医药杂志,1981(10):28-37.
[10] POUSA ID,MATE J,GISBERT JP.Angiogenesis in inflammatory bowel disease[J].Eur J Clin Invest,2008,38(2):73-81.
[2] 徐速,陈浩,曾莉.三棱丸方加减治疗克罗恩病肠道纤维化36例疗效观察[J].结直肠肛门外科杂志,2014,20(6):433-434.
[3] 徐速,曾莉.三棱丸方对克罗恩病肠纤维化中血小板活化治疗作用的研究[J].陕西中医,2017,38(2):144-146.
[4] 徐速,曾莉.三棱丸方对肠上皮细胞上皮间质转化TGFβ1/Smads信号通路的影响[J].辽宁中医杂志,2017,44(1):125-127.
[5] 徐速,曾莉.三棱丸方干预克罗恩病大鼠肠壁纤维化的作用研究[J].辽宁中医杂志,2016,43(10):2188-2191.
[6] VIDELA S,VILASECA J,MEDINA C,et al.Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis[J].J Pharmacol Exp Ther,2006,316(2):940-945.
[7] 吕永慧.克罗恩病的中医诊治思路[J].现代消化及介入诊疗,2010,15(4):244-247.
[8] 姚俊.经验良方全集[M].北京:中国中医药出版社,1995:135-137.
[9] 沈丕安.以活血化瘀为主治疗腹腔内炎性肿块2例[J].上海中医药杂志,1981(10):28-37.
[10] POUSA ID,MATE J,GISBERT JP.Angiogenesis in inflammatory bowel disease[J].Eur J Clin Invest,2008,38(2):73-81.